Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

55.26 -1.36 (-2.40%)

Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

85 86 Next >

2 Dividend Stocks to Buy and Hold For 10 Years ↗

Today 14:18 EST

They are unlikely to resort to dividend cuts anytime soon.

Via The Motley Fool

Topics Intellectual Property

2 Buffett Stocks to Load Up On—And 1 to Ditch ↗

Today 8:20 EST

Via MarketBeat

Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth ↗

January 17, 2026

Via Chartmill

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Via MarketMinute

Topics Economy Intellectual Property

Thursday's session: gap up and gap down stock in the S&P500 index ↗

January 15, 2026

Via Chartmill

3 Value Stocks That Fall Short

January 14, 2026

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

3 S&P 500 Stocks Walking a Fine Line

January 13, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Via StockStory

Topics Stocks

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance

January 12, 2026

The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

January 12, 2026

From Bristol Myers Squibb

Via Business Wire

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

Via MarketMinute

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Via The Motley Fool

Discover which S&P500 stocks are making waves on Wednesday. ↗

January 07, 2026

Via Chartmill

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

Topics Economy Intellectual Property World Trade

1 Top ETF I Plan to Load Up on in 2026 ↗

January 02, 2026

This ETF could produce robust total returns in 2026 and beyond.

Via The Motley Fool

Topics ETFs Stocks

Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

January 02, 2026

From Bristol Myers Squibb

Via Business Wire

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

Via MarketMinute

Topics Intellectual Property

2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

December 31, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the...

Via StockStory

Topics Stocks

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

2 Dividend Stocks to Scoop Up Without Hesitation Right Now ↗

December 31, 2025

These stocks can be great sources of portfolio growth in the years ahead.

Via The Motley Fool

Topics Bankruptcy Initial Public Offering

Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? ↗

December 30, 2025

The stock has been on the rebound for several months, but can it keep the momentum going?

Via The Motley Fool

Topics Intellectual Property

The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year

December 30, 2025

As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever ↗

December 30, 2025

Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.

Via The Motley Fool

Topics Economy Intellectual Property

3 Drug Stocks to Buy at a Discount ↗

December 27, 2025

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Via The Motley Fool

Topics Intellectual Property

Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever ↗

December 24, 2025

If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Co (NYSE:BMY) Presents a Classic Value Investing Case Amid Transition ↗

December 24, 2025

Bristol Myers Squibb (BMY) presents a classic value investing case, trading at a significant discount with strong profitability and a high dividend yield, despite near-term patent challenges.

Via Chartmill

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

85 86 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.